New analysis reveals that over half of patients treated for depression may be eligible for psilocybin-assisted therapy if FDA-approved. A recent study predicts that psilocybin-assisted therapy could aid millions of depression patients in the U.S., covering 56%-62% of those currently treated. This finding underscores the importance of strategic healthcare and insurance planning to harness the […]
Source link